Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition Roche reported a 9% increase in third-quarter sales, driven by strong ...

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while ...

Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...

Roche announces third-quarter and nine-month results. Sanofi holds exclusive talks with CD&R to sell a 50% stake in Opella. Catalent stock faces uncertainty as several pharma companies voice ...

(RTTNews) - Flare Therapeutics has entered into a strategic discovery collaboration with Roche. The partnership will leverage Flare Therapeutics' proteomic and mass spectrometry platform, to discover ...

Roche (RHHBY) announced that a detailed analysis of the positive phase III INAVO120 results, evaluating Itovebi in combination with palbociclib and fulvestrant were published in the New England ...

Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2.1 Patients with HER2-low status may now be eligible for HER2-targeted treatment, ...

In addition to the slow sales and profit growth, the analyst noted that Roche's stock dividend yield is comparatively high, which is reflective of the low growth prospects for the company.

Commentators pointed to the strategic alliance Roche agreed with Tesaro earlier this year, which they suggested could be moving in the direction of a merger, perhaps as early as next month.

In addition to the slow sales and profit growth, the analyst noted that Roche's stock dividend yield is comparatively high, which is reflective of the low growth prospects for the company. This high ...